RedHill Biopharma Ltd - Company Profile (NASDAQ:RDHL)

About RedHill Biopharma Ltd -

RedHill Biopharma Ltd - logoRedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company's products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT and RHB-101. RHB-105 is a fixed-dose oral combination therapy. RHB-104 is an antibiotic combination therapy in oral capsule formulation. BEKINDA is an oral, extended-release (approximately 24 hours), once-daily pill formulation of the antiemetic drug ondansetron. RHB-106 is an encapsulated oral bowel preparation. YELIVA (ABC294640) is a Phase II-stage sphingosine kinase-2 (SK2) selective inhibitor. MESUPRON is a urokinase-type plasminogen activator (uPA) inhibitor. RP101 is a heat shock protein 27 (Hsp27) inhibitor. RIZAPORT is an oral fast dissolving thin film formulation. RHB-101 is a once daily controlled release formulation of Carvedilol.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RDHL
  • CUSIP:
Key Metrics:
  • Previous Close: $9.42
  • 50 Day Moving Average: $9.95
  • 200 Day Moving Average: $12.30
  • 52-Week Range: $8.77 - $16.54
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.13
  • P/E Growth: 0.00
  • Market Cap: $118.55M
  • Outstanding Shares: 12,747,000
  • Beta: 0.56
Profitability:
  • Return on Equity: -53.96%
  • Return on Assets: -47.25%
Debt:
  • Current Ratio: 5.84%
  • Quick Ratio: 5.84%
Additional Links:
Companies Related to RedHill Biopharma Ltd -:

Analyst Ratings

Consensus Ratings for RedHill Biopharma Ltd - (NASDAQ:RDHL) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (211.83% upside)

Analysts' Ratings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetDetails
2/24/2017FBR & CoReiterated RatingOutperform -> Outperform$36.00 -> $25.00View Rating Details
10/7/2016HC WainwrightSet Price TargetBuy$33.00View Rating Details
3/29/2016NomuraReiterated RatingBuyView Rating Details
2/27/2016Roth CapitalReiterated RatingBuyView Rating Details
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00View Rating Details
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00View Rating Details
7/2/2015MLV & Co.Initiated CoverageBuy$33.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q116($0.58)($0.06)ViewListenView Earnings Details
4/20/2016Q1($0.48)$0.04ViewListenView Earnings Details
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details
6/6/2014($0.44)$0.39ViewN/AView Earnings Details
4/30/2014($0.44)$0.39ViewN/AView Earnings Details
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Current Year EPS Consensus Estimate: $-2.35 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.49)($0.49)($0.49)
Q2 20161($0.54)($0.54)($0.54)
Q3 20162($0.61)($0.53)($0.57)
Q4 20162($0.73)($0.65)($0.69)
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.65)($0.65)($0.65)
Q3 20171($0.65)($0.65)($0.65)
Q4 20171$0.79$0.79$0.79
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateHeadline
News IconAre Analysts Optimistic About Where Redhill Biopharma Ltd. (NASDAQ:RDHL) is Heading? - Winfield Review (NASDAQ:RDHL)
winfieldreview.com - February 24 at 8:11 AM
streetinsider.com logoRedhill Biopharma (RDHL) PT Lowered to $25 at FBR Capital Citing Dilutive Dec '16 Public Offering; 4Q Results Positive - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - February 24 at 8:11 AM
News IconRedhill Biopharma Ltd. (NASDAQ:RDHL) to Post $-0.63 Earnings Per Share: Analysts - Winfield Review (NASDAQ:RDHL)
winfieldreview.com - February 24 at 12:36 AM
globenewswire.com logoRedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website - GlobeNewswire (press release) (NASDAQ:RDHL)
globenewswire.com - February 24 at 12:36 AM
finance.yahoo.com logoRedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website (NASDAQ:RDHL)
finance.yahoo.com - February 23 at 7:35 PM
News IconReviewing Individual Broker Targets Of Redhill Biopharma Ltd. (RDHL) - NewsDen (NASDAQ:RDHL)
newsden.net - February 23 at 8:32 AM
News IconRedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis - Clinical Leader (NASDAQ:RDHL)
www.clinicalleader.com - February 23 at 8:32 AM
finance.yahoo.com logoRedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results (NASDAQ:RDHL)
finance.yahoo.com - February 23 at 8:32 AM
News IconSell-side is Weighing in on Redhill Biopharma Ltd. (NASDAQ:RDHL) Earnings - Aiken Advocate (NASDAQ:RDHL)
aikenadvocate.com - February 23 at 12:39 AM
streetinsider.com logoRedHill Biopharma (RDHL) Treats Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - February 23 at 12:39 AM
nasdaq.com logoAPOP Pops On Study Data, EYEG Catches Investors' Eyes, CDTX Loses Radiance (NASDAQ:RDHL)
www.nasdaq.com - February 22 at 9:31 AM
4-traders.com logoDGAP-News: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA(R) Phase III Study for Acute Gastroenteritis (NASDAQ:RDHL)
www.4-traders.com - February 22 at 9:31 AM
News IconRedHill Biopharma Completes Treatment of Last Patient in BEKINDA(R) Phase III Study for Acute Gastroenteritis (NASDAQ:RDHL)
www.stock-world.de - February 21 at 5:23 PM
streetinsider.com logoRedHill Biopharma (RDHL) Treats Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis (NASDAQ:RDHL)
www.streetinsider.com - February 21 at 5:23 PM
us.rd.yahoo.com logoRedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis (NASDAQ:RDHL)
us.rd.yahoo.com - February 21 at 5:23 PM
globenewswire.com logoRedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017 - GlobeNewswire (press release) (NASDAQ:RDHL)
globenewswire.com - February 18 at 8:13 AM
News IconRedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:RDHL)
www.bioportfolio.com - February 17 at 7:59 PM
News IconRedHill Expects Bekinda Top-Line Data In Q2 (NASDAQ:RDHL)
www.talkmarkets.com - February 14 at 5:10 AM
finance.yahoo.com logoRedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis (NASDAQ:RDHL)
finance.yahoo.com - February 13 at 8:52 AM
News IconAnalysts Chiming in on Shares of Redhill Biopharma Ltd. (NASDAQ ... - Rives Journal (NASDAQ:RDHL)
rivesjournal.com - February 7 at 8:31 AM
finance.yahoo.com logo4 Drug Stocks that are Broker Favorites (NASDAQ:RDHL)
finance.yahoo.com - February 7 at 8:31 AM
finance.yahoo.com logoRedHill Biopharma to Present at the BIO CEO & Investor Conference (NASDAQ:RDHL)
finance.yahoo.com - February 6 at 8:49 AM
News IconWhat are the Technical Charts Saying About Redhill Biopharma Ltd. (RDHL) - Sherwood Daily (NASDAQ:RDHL)
sherwooddaily.com - February 2 at 3:50 AM
News IconPossible Cystic Fibrosis Treatment — Disease Prevalent Among Ashkenazic Jews (NASDAQ:RDHL)
jewishbusinessnews.com - January 18 at 8:07 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Beacon (NASDAQ:RDHL)
wsbeacon.com - January 18 at 8:09 AM
News IconWill The Needle Move For Redhill Biopharma Ltd. (NASDAQ:RDHL) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:RDHL)
wsbeacon.com - January 14 at 5:30 AM
us.rd.yahoo.com logo6:03 am RedHill Biopharma provides an update on key programs, potential milestones and estimated timelines (NASDAQ:RDHL)
us.rd.yahoo.com - January 12 at 8:09 PM
News IconAre Institutions Jumping Ship on RedHill Biopharma Ltd. (NASDAQ:RDHL) - Wall Street Beacon (NASDAQ:RDHL)
wsbeacon.com - January 12 at 1:12 AM
streetinsider.com logoRedHill Biopharma (RDHL) Begins Dosing in PK Study with RHB-105 for H. pylori Infection - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - January 12 at 1:12 AM
streetinsider.com logoRedHill Biopharma (RDHL) Says RHB-104 Granted Qualified Infectious Disease Product (QIDP) from FDA - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - January 12 at 1:12 AM
News IconRedHill Biopharma Announces YELIVA(R) (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference (NASDAQ:RDHL)
www.itbusinessnet.com - January 11 at 8:12 PM
us.rd.yahoo.com logoRedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections (NASDAQ:RDHL)
us.rd.yahoo.com - January 11 at 8:11 PM
streetinsider.com logoRedHill Biopharma (RDHL) Begins Dosing in PK Study with RHB-105 for H. pylori Infection (NASDAQ:RDHL)
www.streetinsider.com - January 10 at 9:12 PM
us.rd.yahoo.com logoRedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium (NASDAQ:RDHL)
us.rd.yahoo.com - January 10 at 9:12 PM
finance.yahoo.com logoRedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection (NASDAQ:RDHL)
finance.yahoo.com - January 10 at 9:12 PM
investornewswire.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Records An Impact Score Of 87 - Investor Newswire (NASDAQ:RDHL)
www.investornewswire.com - January 9 at 8:09 PM
streetinsider.com logoRedHill Biopharma (RDHL) Announces Positive RHB-105 Phase III Study Results for H. pylori Infection - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - January 9 at 8:09 PM
globenewswire.com logoRedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management - GlobeNewswire (press release) (NASDAQ:RDHL)
globenewswire.com - January 9 at 7:27 AM
finance.yahoo.com logoRedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management (NASDAQ:RDHL)
finance.yahoo.com - January 9 at 7:27 AM
News IconRedHill Biopharma Ltd RDHL Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RDHL)
www.bioportfolio.com - January 8 at 5:09 AM
us.rd.yahoo.com logoRedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference (NASDAQ:RDHL)
us.rd.yahoo.com - January 8 at 5:09 AM
streetinsider.com logoRedHill Biopharma (RDHL) Announces Presentation of YELIVA ... - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - January 6 at 8:17 PM
News IconHome Business RedHill Biopharma Ltd – (NASDAQ: RDHL) Stock Rating Reiterated at FBR &... - BNB Daily (blog) (NASDAQ:RDHL)
www.baseball-news-blog.com - January 6 at 1:16 AM
finance.yahoo.com logoRedHill Biopharma Announces New Research Collaboration with Aarhus University for Oncology Drug MESUPRON (NASDAQ:RDHL)
finance.yahoo.com - January 6 at 1:16 AM
finance.yahoo.com logo7:02 am RedHill Biopharma announces the signing of a new collaboration agreement with the Department of Molecular Biology & Genetics of Aarhus University for the evaluation of phase II-stage oncology drug candidate Mesupron (NASDAQ:RDHL)
finance.yahoo.com - January 6 at 1:16 AM
streetinsider.com logoRedHill Biopharma (RDHL) to Present Positive Results of the First Phase III study with RHB-105 at Innovations in ... - StreetInsider.com (NASDAQ:RDHL)
www.streetinsider.com - January 4 at 9:11 PM
streetinsider.com logoRedHill Biopharma (RDHL) to Present Positive Results of the First Phase III study with RHB-105 at Innovations in Gastroenterology 2017 Symposium (NASDAQ:RDHL)
www.streetinsider.com - January 4 at 4:11 PM
finance.yahoo.com logoRedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium (NASDAQ:RDHL)
finance.yahoo.com - January 4 at 4:11 PM
finance.yahoo.com logoBlog Coverage RedHill Biopharma Signs Co-Promotion Agreement with Concordia and Announces Exercise of Underwriters Options (NASDAQ:RDHL)
finance.yahoo.com - January 4 at 4:11 PM
News IconRedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal (NASDAQ:RDHL)
www.biospace.com - January 4 at 12:16 AM

Social

What is RedHill Biopharma Ltd -'s stock symbol?

RedHill Biopharma Ltd - trades on the NASDAQ under the ticker symbol "RDHL."

Where is RedHill Biopharma Ltd -'s stock going? Where will RedHill Biopharma Ltd -'s stock price be in 2017?

4 brokers have issued 12-month price objectives for RedHill Biopharma Ltd -'s stock. Their predictions range from $25.00 to $33.00. On average, they anticipate RedHill Biopharma Ltd -'s share price to reach $29.00 in the next twelve months.

What are analysts saying about RedHill Biopharma Ltd - stock?

Here are some recent quotes from research analysts about RedHill Biopharma Ltd - stock:

  • FBR & Co analysts commented, "RedHill Biopharma reported 4Q16 results that showed the company strongly positioned to achieve its objectives in 2017. Specifically, we think positive results from multiple clinical programs position RedHill to achieve value inflection points, including a top-line readout from the GUARD Phase III study with Bekinda in gastroenteritis, a second independent DSMB meeting for the MAP US Phase III study with RHB-104 in Crohn's disease (CD), and initiation of a confirmatory Phase III study with RHB-105 for H. pylori infection, which are all expected in 2Q17. While the balance sheet strengthened in 1Q17 (pro forma $66M in cash, no debt), the public offering completed in December 2016 was dilutive. Thus, we adjusted our price target from $36 to $25 to reflect the dilution as well as an adjustment in our projected timing for RHB-104 approval in CD to YE18. We continue to look for these milestones to be catalysts for the stock and reiterate our Outperform rating." (2/24/2017)
  • According to Zacks Investment Research, "RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill's proprietary pipeline includes: RHB-105 - a combination therapy for H.pylori infection; RHB-104 - a combination therapy for Crohn's disease and multiple sclerosis; BEKINDA - a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA - an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON - a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 - currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT - an oral thin film formulation of rizatriptan for acute migraines. " (2/9/2017)

Who owns RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd (4.76%), EMC2 FUND LTD. Total Shares: 2,195,133 (11.87%), Orbimed Advisors LLC (4.43%), Menora Mivtachim Holdings LTD. (3.30%), Broadfin Capital LLC (1.97%) and Van ECK Associates Corp (0.23%).

Who sold RedHill Biopharma Ltd - stock? Who is selling RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC.

Who bought RedHill Biopharma Ltd - stock? Who is buying RedHill Biopharma Ltd - stock?

RedHill Biopharma Ltd -'s stock was purchased by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Renaissance Technologies LLC and Van ECK Associates Corp.

How do I buy RedHill Biopharma Ltd - stock?

Shares of RedHill Biopharma Ltd - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of RedHill Biopharma Ltd - stock cost?

One share of RedHill Biopharma Ltd - stock can currently be purchased for approximately $9.30.

RedHill Biopharma Ltd - (NASDAQ:RDHL) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for RedHill Biopharma Ltd - (NASDAQ:RDHL)

Earnings History Chart

Earnings by Quarter for RedHill Biopharma Ltd - (NASDAQ:RDHL)

Dividend History Chart

Dividend Payments by Quarter for RedHill Biopharma Ltd - (NASDAQ:RDHL)

Last Updated on 2/24/2017 by MarketBeat.com Staff